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PsyChiAtRiC AsPeCts of hePAtitis C tReAtment
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sUmmARy – hepatitis C is a public health problem worldwide. Currently recommended the-
rapy for the treatment of hepatitis C, pegylated interferon-alpha and ribavirin, when applied in com-
bination, are often associated with the risk of developing mood disorders, depression and anxiety. 
Previously, the existence of psychiatric comorbidity was the reason for therapy discontinuation, but 
current guidelines allow such treatment despite the presence of psychiatric illness. Close cooperati-
on with psychiatrists is highly recommended for the treatment of patients with psychiatric comorbid 
disease in order to motivate the patient for treatment, stabilize his mental condition, educate him 
about the possible side effects, and regularly monitor the patient, so the treatment can be carried out 
safely and successfully. Therefore, a multidisciplinary approach is essential for successful treatment 
of hepatitis C virus infections.
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Introduction
hepatitis C is a public health problem worldwide 
and the prevalence of hepatitis C virus (hCV) infec-
tion varies throughout the world. infection with hCV 
is self-limited in a small minority of infected persons, 
so hCV is a major cause of acute and chronic hepati-
tis. Currently recommended therapy for the treatment 
of hepatitis C is pegylated interferon-alpha (ifn-α) 
and ribavirin. When applied in combination, they 
are often associated with the risk of developing mood 
disorders, depression and anxiety. Previously, the ex-
istence of psychiatric comorbidity was the reason for 
therapy discontinuation, but current guidelines allow 
such treatment despite the presence of psychiatric ill-
ness. Close cooperation with psychiatrists is highly 
recommended for the treatment of patients with psy-
chiatric comorbid disease. Psychiatrist should mo-
tivate the patient for treatment, stabilize his mental 
condition, educate him about the possible side effects, 
and regularly monitor the patient, so the treatment 
can be carried out safely and successfully.
Epidemiology and Symptomatology
Patients suffering from hCV infection tend to 
develop significant comorbidity and mortality, often 
at an early age. hCV is responsible for 20% of acute 
hepatitis, 89% of chronic hepatitis, 40% of liver cir-
rhosis, 70% of hepatocellular carcinomas and 30% of 
liver transplants1. in Croatia, 1.7% of the population 
or 75,000 people are infected with hCV. Without ad-
dressing the problem appropriately, the negative trend 
will continue and the number of infected individuals, 
as well as those who will develop severe complications 
of the disease can be expected to rise significantly2. 
hCV infection is transmitted through infected blood. 
Until the introduction of mandatory testing of volun-
teer blood donors (in Croatia since 1993), blood trans-
fusion and transfusion of blood products were the 
main transmission path of hepatitis C, even in 85% 
of cases.
in Croatia, 90% of all new cases of hepatitis C are 
caused by intravenous drug use, the use of common sy-
ringes and needles, in which the risk of infection rises 
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up to 90%. hCV transmission by sexual intercourse 
and during birth from infected mother to newborn 
child (perinatal time) is less common and the risk of 
transmission is about 5%. After birth, if the newborn 
is not infected, maternal anti-hCV antibodies disap-
pear from the blood in 6-12 months. Those children 
need to be re-tested at the age of 3 months, and regu-
larly followed up to 12 months after birth. The virus 
can be present in the milk of a hCV-positive mother, 
but there is no evidence of infection during lactation. 
other ways of infection are much less common (acci-
dental thrust on needles, use of razors, toothbrushes, 
tattooing, etc.). in as many as 20% of infected persons, 
the exact transmission path cannot be determined3. 
The hCV incubation period to the onset of acute 
hepatitis C is 15 to 50 days, 6 weeks on an average. 
The presence of hCV RnA in the blood can only 
be confirmed by a special assay. in the initial hCV 
infection, only mild flu-like illness can be recorded, 
but usually there are no symptoms that could indi-
cate an infection. nonspecific symptoms occur in only 
25%-30% of hCV infected patients. Therefore, acute 
hepatitis C is rarely diagnosed and in the majority of 
patients virus is detected when the disease has already 
widespread and is in the phase of chronic hepatitis.
Chronic hepatitis is diagnosed when liver inflam-
mation lasts longer than six months and is accom-
panied by the following symptoms: loss of appetite, 
nausea, vomiting, abdominal pain, fever, joint pain, 
exhaustion and a feeling of constant fatigue. in 75%-
85% of cases, acute hCV turns to the chronic form 
and is characterized by permanent damage to the liv-
er. it is believed that hCV infection causes 50%-70% 
of all cases of malignant liver disease. 
According to recent data, 46% of intravenous drug 
users are hepatitis C positive, while 10% are hepati-
tis B positive2. These data point to the importance of 
testing drug users for the infection and referring them 
to treatment in the early stages of infection in order to 
prevent severe complications.
in Croatia, available pharmacotherapy for the 
treatment of hepatitis C are pegylated ifn-α, ifn-α 
(conventional interferon) and ribavirin3,4. The pre-
dominant genotypes are genotype 1 and 3, while 
other genotypes occur by far less frequently. Determi-
nation of hCV genotype is important in determining 
the length of treatment. 
Etiology
There are various theories of the biological mecha-
nisms of mood disorders induced by ifn therapy. 
hCV changes brain metabolism and replicates in the 
brain tissue5,6.
The etiology of depression caused by ifn thera-
py rests on especially reduced values of 5 ht (sero-
tonin) receptors. The disorder involves changes in the 
hypothalamic-pituitary-adrenocortical (hPA) axis, 
activation of inflammatory cytokines, reduced levels 
of peptidases, increased intercellular adhesion of mol-
ecule 1 (iCAm-1) and increased levels of nitric oxide. 
storage levels of serotonin and monoamine oxidase B 
activity (mAo-B) are significantly lower in chronic 
hCV patients. Genetic differences in the 5-httL-
PR (serotonin ‘reuptake’ transporters) are associated 
with major depression during ifn therapy7. ifn-α 
therapy changes other monoamines such as dopamine 
and norepinephrine, which can also cause depression. 
ifn-α directly stimulates the release of corticotropin 
hormone, which increases the production of adreno-
corticotropic hormone, resulting in increased cortisol, 
and these stress hormones are directly responsible for 
anxiety and depressive symptoms8.
The treatment of choice for chronic hepatitis C is 
six- or twelve-month therapy with ifn-α and riba-
virin, which is effective in a substantial proportion of 
patients (40%-88%)9,10. ifn-α significantly modu-
lates the function of cytokine system and enhances 
antiviral immune response11. Ribavirin does not in-
duce neuropsychiatric side effects directly, although 
it may disturb thyroid function and indirectly affect 
brain function12. Low-doses of ifn-α therapy are of-
ten associated with neuropsychiatric side effects, most 
frequently depression, mild cognitive impairment and 
fatigue, which disappear upon cessation of ifn-α 
in almost all patients13,14. Psychotic disturbances as 
adverse neuropsychiatric side effects of ifn therapy 
have been observed infrequently15-17.
Although depression is the most widely reported 
neuropsychiatric side effect of ifn therapy, clinicians 
should be aware that other symptoms, such as sim-
ple fatigue, anxiety, insomnia, irritability, cognitive 
impairment, and mania, may occur. suicide is a real 
threat for patients on treatment for hCV. suicidal 
thoughts are a common complication of ifn therapy 
and stem from a combination of depressive symptoms 
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along with anxiety, agitation, and irritability. Diep-
erink et al. report on the rates of suicidal ideation as 
high as 27% in hCV patients who were not on ifn 
and 43% of patients with ifn endorsed suicide ide-
ation at some point during therapy18. screening for 
suicide ideation must occur at regular, closely spaced 
intervals. 
Treatment of Psychiatry Symptoms during IFN 
Therapy
All patients scheduled for ifn therapy initiation 
should undergo psychosocial screening, which at a 
minimum should include past psychiatric history and 
current assessment for mood or anxiety symptoms, 
substance use, and suicidality. it is useful to employ 
depression screening tools such as the Beck Depres-
sion inventory (BDi), Zung self-Rating Depression 
scale, hamilton Depression Rating scale, hamilton 
Anxiety scale or neurotoxicity Rating scale.
The primary treatment for ifn-induced depres-
sion is traditional antidepressant therapy. neverthe-
less, a number of adjuvant medications have been uti-
lized to assist with symptomatic relief19. 
Depressive disorder starts usually after 1-3 months 
of ifn therapy introduction and the rate of depres-
sion is higher among patients on intravenous ifn 
compared to subcutaneous administration. Co-ad-
ministration of ribavirin contributes to a higher rate 
of depression. in addition to psychological complica-
tions, there is a number of somatic side effects that 
are encountered such as fever, chills, muscle pain and 




























Bupropion has a potential for seizure
in combination with ifn. 
Duloxetine may be problematic in patients with 
chronic liver disease.






may cause heightened anxiety or insomnia in 
some patients.
traditional stimulants such as methylphenidate 
may exacerbate psychotic symptoms.
Anxiolytics Lorazepam
Use short half-life medications (glucuronidated) 
because of liver disease: use caution with 
addictive medications in this population.
Dopamine agonists Amantadine Depression still experimental and with limited evidence.
hypnotics Zolpidem trazodonemirtazapine insomnia





first-line treatment would be atypical 
antipsychotics, pending
further psychiatric evaluation.
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sweating, which is particularly risky in this popula-
tion because addicts can evoke memories of the with-
drawal symptoms and this may lead to relapse as a way 
of removing the somatic side effects20.
An overview of the possible options of medications 
is shown in table 121, and is by no means inclusive 
of all possible therapies. Guidelines for screening and 
ongoing monitoring and specific treatment recom-
mendations for ifn-induced depression are reviewed 
in table 221.
selective serotonin reuptake inhibitors (ssRis) 
clearly appear to be optimal first-line therapy for ifn-
induced depressive disorders. Case reports and limited 
studies can be found for many of the ssRis, including 
sertraline, citalopram, and paroxetine. There is some 
evidence for excellent results with sertraline, poten-
tially because of the serotonergic and dopaminergic 
effects of this medication. sertraline can be somewhat 
activating for some patients and may induce addition-
al anxiety, which is less common with citalopram or 
escitalopram.
Antidepressants with serotonergic activity and 
benzodiazepines also have value in the treatment of 
irritability associated with ifn therapy22.
Depression Treatment during IFN Therapy
some studies advocate the use of prophylactic an-
tidepressants for patients who have a family history of 
depression or had an episode of depression in the past, 
but there is still a lack of evidence to support such use 
of antidepressants23.
for the patients suffering from depression, it is sug-
gested that ifn treatment be delayed until improve-
ment of the mental state24. Depression during ifn 
treatment is treated with antidepressants combined 
with psychotherapeutic support. Antidepressants, 
particularly ssRis, should be introduced 2-3 weeks 
Table 2. Suggested guidelines for treatment of interferon (IFN)-induced depressive disorders21
1. All candidates cleared for ifn medically should receive psychiatric screening: past psychiatric history; current 
screening for mood or anxiety symptoms – useful to employ screening tools such as Beck Depression inven-
tory (BDi), Zung self-Rating Depression scale; inquire about substance use; educate patients about the risk of 
interferon-induced neuropsychiatric disorders and how to recognize symptoms; explain that treatment options are 
available if these problems emerge.
2. Patients require psychiatric management in the following circumstances: complex psychiatric history (severe de-
pression, suicide ideation, bipolar disorder, schizophrenia, anxiety disorders, etc.); history of alcohol or substance 
use disorder; patient in ongoing psychiatric treatment; history of significant psychiatric hospitalizations.
3. in patients with current depression or anxiety of moderate or severe intensity or patients with a history of severe 
depression or ifn-induced depression who are currently asymptomatic: offer pre-treatment with antidepressant 
at least 4 weeks before interferon; delay interferon therapy for patients whose symptoms remain significant after 
4 weeks; monitor at a minimum every two weeks during first three months of treatment (frequency may decrease 
after that time to every two to four weeks).
4. for patients who do not require pre-treatment: initiate interferon; monitor at a minimum every 2 weeks during 
the first three months, then every 2 to 4 weeks thereafter – perform psychiatric screens and ask about suicidal 
thoughts at every visit; if depressive symptoms occur, initiate antidepressant therapy immediately; be aware that 
some patients may minimize symptoms because of concern regarding discontinuation of treatment; during inter-
feron therapy, physical symptoms may be secondary to interferon and not frank depression. focus especially on 
more psychological symptoms such as depressed mood, anhedonia, ruminatory thoughts, helpless and hopeless 
feelings, crying spells, irritability, social withdrawal, and guilt.
5. if depression or anxiety symptoms worsen during treatment, increase antidepressant dosage and consider augmen-
tation with second antidepressant from a different class. Refer immediately for emergent psychiatric assessment/
hospitalization and discontinue interferon for the following circumstances: suicide or homicide ideation; hypoma-
nia, mania; severe depression, anxiety, or other psychiatric symptoms; psychosis.
6. Throughout treatment, closely monitor patients with concurrent or previous substance use disorders for relapse.
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before the start of ifn therapy. following the latest 
guidance, if depression occurs during the treatment of 
hepatitis C, it should be treated without interrupting 
ifn therapy. Among the ssRis, the least potent in 
interactions with certain liver cytochrome oxidase en-
zyme systems, such as escitalopram, citalopram, ser-
traline or paroxetine, should be used in treatment25.
in severe hepatic impairment, the dose of these 
drugs should be reduced, and in patients on metha-
done maintenance therapy, paroxetine (which is safe 
for the liver) should be used cautiously because it 
increases the concentration of methadone. it is pos-
sible to prescribe an antidepressant that bypasses the 
cytochrome oxidase enzyme, e.g., tianeptine. other 
antidepressants are still secondary options (fluoxetine, 
fluvoxamine, mirtazapine, venlafaxine, duloxetine, 
moclobemide, maprotiline, clomipramine), and a 
higher degree of caution is required when prescribing 
them because of their stronger impact on the hepatic 
enzyme systems (they are toxic for the liver).
Those patients who had other psychiatric comor-
bidities prior to the commencement of the treatment 
for hepatitis C are advised to stabilize on appropriate 
pharmacotherapy before starting ifn therapy, in or-
der to reduce its destabilizing effect. When prescribing 
antipsychotics to patients with hepatic impairment, 
drugs with a low degree of risk for progression of liver 
damage such as zuklopentixol, flupentixol, haloperi-
dol, sulpiride, amisulpride and aripiprazole, should be 
opted. Promazine, clozapine, quetiapine, olanzapine 
and risperidone have a moderately high risk for liver 
damage.
Benzodiazepines and hypnotics may help with 
irritability, anxiety and insomnia, but they present a 
potential risk of addiction. if they are prescribed, then 
it should be those that are metabolized by glucuroni-
dation, like lorazepam, oxazepam and temazepam. 
hypnotics (non-benzodiazepines) that could be pre-
scribed, such as zolpidem and zopiclona, are by far 
less addictive. sedating antidepressants, such as mir-
tazapine and trazodone, could also be effective.
for the treatment of opiate addicts, it is essential 
to stabilize them on substitution therapy (methadone, 
buprenorphine) to reduce the risk of relapse and there-
fore interruption of the treatment of hepatitis C26. for 
all comorbid psychiatric disorders during the treat-
ment of hepatitis C, frequent psychiatric support is 
needed along with psychopharmacy, so that patients 
could successfully endure treatment till the end27.
Conclusion
it may be suggested that early identification of 
psychiatry disorders and appropriate psychopharma-
cological treatment might prevent subsequent devel-
opment of serious debilitating symptoms. Consider-
ing all specifics of the treatment of hepatitis C, it is 
necessary to provide regular psychiatric consultations 
not only for patients who have risk factors to develop 
neuropsychiatric side effects, but for all patients un-
dergoing long-term treatment with ifn. Therefore, 
a multidisciplinary approach (psychiatrists, hepatolo-
gists, nurses, etc.) is essential for successful treatment 
of hCV infections.
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sažetak
PsihiJAtRiJsKi AsPeKti LiJeČenJA hePAtitisA C
D. Bundalo Vrbanac, D. Buljan, I. Sindik, J. Gelo i L. Nauković Sakoman
hepatitis C je javnozdravstveni problem u svijetu. trenutno se u liječenju hepatitisa C preporučuje terapija pegiliranim 
interferonom-alfa i ribavirinom, a ta kombinacija se povezuje s rizikom razvoja poremećaja raspoloženja, depresije i ank-
sioznosti. Ranije je postojanje psihijatrijskog komorbiditeta bio razlog za ukidanje liječenja, ali današnje smjernice dozvo-
ljavaju takvo liječenje unatoč postojanju psihijatrijskih bolesti. Preporučuje se bliska suradnja s psihijatrima kod liječenja 
bolesnika s psihijatrijskim komorbiditetom kako bi se bolesnika motiviralo za liječenje, stabiliziralo njegovo mentalno sta-
nje i upoznalo ga s mogućim nuspojavama. Uz ovakvo kontinuirano praćenje bolesnika liječenje se može provoditi sigurno 
i uspješno. stoga je multidisciplinarni pristup neophodan za uspješno liječenje infekcije virusom hepatitisa C.
Ključne riječi: Hepatitis C; Interferoni; Psihijatrija; Komorbiditet
